Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGC NASDAQ:INBX NASDAQ:IRD NASDAQ:LIMN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.09-6.8%$1.40$0.77▼$8.65$215.12M0.736.58 million shs10.56 million shsINBXInhibrx Biosciences$22.96$14.70$10.80▼$24.30$332.37M-0.0497,484 shs114,286 shsIRDOpus Genetics$1.10-0.9%$1.00$0.65▼$1.75$66.22M-0.02510,142 shs93,990 shsLIMNLiminatus Pharma$5.59-11.7%$0.00$4.40▼$33.66$164.67MN/A330,121 shs141,707 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth-6.84%-11.38%-26.35%-7.63%-84.73%INBXInhibrx Biosciences0.00%+15.15%+57.58%+100.17%+65.66%IRDOpus Genetics-0.90%+3.77%+13.40%+49.64%+109,999,900.00%LIMNLiminatus Pharma-11.69%-10.99%+558,999,900.00%+558,999,900.00%+558,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGCCanopy Growth0.4041 of 5 stars0.02.00.00.02.70.01.3INBXInhibrx Biosciences2.4497 of 5 stars0.03.00.04.62.71.71.3IRDOpus Genetics1.8569 of 5 stars3.50.00.00.02.70.00.6LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 1.00SellN/AN/AINBXInhibrx Biosciences 2.00HoldN/AN/AIRDOpus Genetics 3.00Buy$7.33566.67% UpsideLIMNLiminatus Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IRD, INBX, CGC, and LIMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/30/2025CGCCanopy GrowthPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight5/15/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$225.65M0.89N/AN/A$1.90 per share0.57INBXInhibrx Biosciences$200K1,662.30$114.80 per share0.20$9.23 per share2.49IRDOpus Genetics$10.99M5.97N/AN/A$0.21 per share5.24LIMNLiminatus PharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$429.86M-$4.04N/AN/AN/A-195.76%-88.54%-40.78%8/8/2025 (Estimated)INBXInhibrx Biosciences$1.69B$116.750.20N/AN/AN/A-85.12%-58.90%8/12/2025 (Estimated)IRDOpus Genetics-$57.53M-$2.10N/AN/AN/A-429.42%-283.28%-144.32%8/12/2025 (Estimated)LIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/ALatest IRD, INBX, CGC, and LIMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025INBXInhibrx Biosciences-$2.92N/AN/AN/AN/AN/A8/12/2025N/AIRDOpus Genetics-$0.25N/AN/AN/A$4.27 millionN/A8/8/2025Q1 2026CGCCanopy Growth-$0.10N/AN/AN/A$64.98 millionN/A5/30/2025Q4 2025CGCCanopy Growth-$0.28-$0.94-$0.66-$1.00$71.84 million$45.30 million5/15/2025Q1 2025IRDOpus Genetics-$0.34-$0.32+$0.02-$0.24$4.00 million$4.30 million5/14/2025Q4 2024INBXInhibrx Biosciences-$2.55-$2.80-$0.25-$2.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ALIMNLiminatus PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.623.122.10INBXInhibrx Biosciences1.045.125.12IRDOpus GeneticsN/A1.981.98LIMNLiminatus PharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%INBXInhibrx Biosciences82.46%IRDOpus Genetics14.97%LIMNLiminatus PharmaN/AInsider OwnershipCompanyInsider OwnershipCGCCanopy Growth1.30%INBXInhibrx BiosciencesN/AIRDOpus Genetics6.60%LIMNLiminatus PharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150183.87 million181.48 millionOptionableINBXInhibrx Biosciences16614.48 millionN/AOptionableIRDOpus Genetics1459.66 million55.72 millionN/ALIMNLiminatus PharmaN/A26.01 millionN/AN/AIRD, INBX, CGC, and LIMN HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Liminatus Pharma (NASDAQ:LIMN) to "Hold"July 14 at 2:09 AM | americanbankingnews.comLiminatus Pharma: CD47 Hasn't Worked For Anyone, But Is This The Exception?June 24, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts LoomMicrosoft Stock Holds Steady as AI Drives Workforce ShiftBy Chris Markoch | June 23, 2025View Microsoft Stock Holds Steady as AI Drives Workforce ShiftRegional Bank Buybacks: 5 Institutions Making Big MovesBy Leo Miller | June 24, 2025View Regional Bank Buybacks: 5 Institutions Making Big MovesCould Dutch Bros Dethrone Starbucks? Why Investors Are Perking UpBy Jordan Chussler | July 7, 2025View Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking UpIRD, INBX, CGC, and LIMN Company DescriptionsCanopy Growth NASDAQ:CGC$1.09 -0.08 (-6.84%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.09 +0.00 (+0.37%) As of 07/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Inhibrx Biosciences NASDAQ:INBX$22.96 0.00 (0.00%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$22.92 -0.04 (-0.17%) As of 07/15/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Opus Genetics NASDAQ:IRD$1.10 -0.01 (-0.90%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.10 +0.00 (+0.45%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Liminatus Pharma NASDAQ:LIMN$5.59 -0.74 (-11.69%) As of 07/15/2025 04:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
